193 related articles for article (PubMed ID: 19728975)
21. Can contrast-enhanced US with targeted microbubbles monitor the response to antiangiogenic therapies?
Kruskal JB
Radiology; 2008 Feb; 246(2):339-40. PubMed ID: 18227533
[No Abstract] [Full Text] [Related]
22. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
Line BR; Mitra A; Nan A; Ghandehari H
J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
[TBL] [Abstract][Full Text] [Related]
23. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
Jin F; Xie Z; Kuo CJ; Chung LW; Hsieh CL
Cancer Gene Ther; 2005 Mar; 12(3):257-67. PubMed ID: 15565180
[TBL] [Abstract][Full Text] [Related]
24. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.
Warram JM; Sorace AG; Saini R; Umphrey HR; Zinn KR; Hoyt K
J Ultrasound Med; 2011 Jul; 30(7):921-31. PubMed ID: 21705725
[TBL] [Abstract][Full Text] [Related]
25. Value of contrast-enhanced ultrasonography in prostate cancer.
Kundavaram CR; Halpern EJ; Trabulsi EJ
Curr Opin Urol; 2012 Jul; 22(4):303-9. PubMed ID: 22617061
[TBL] [Abstract][Full Text] [Related]
26. Tumor vascularity: evaluation in a murine model with contrast-enhanced color Doppler US effect of angiogenesis inhibitors.
Iordanescu I; Becker C; Zetter B; Dunning P; Taylor GA
Radiology; 2002 Feb; 222(2):460-7. PubMed ID: 11818614
[TBL] [Abstract][Full Text] [Related]
27. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1.
Becker CM; Farnebo FA; Iordanescu I; Behonick DJ; Shih MC; Dunning P; Christofferson R; Mulligan RC; Taylor GA; Kuo CJ; Zetter BR
Cancer Biol Ther; 2002; 1(5):548-53. PubMed ID: 12496487
[TBL] [Abstract][Full Text] [Related]
29. Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Mancini M; Greco A; Salvatore G; Liuzzi R; Di Maro G; Vergara E; Chiappetta G; Pasquinelli R; Brunetti A; Salvatore M
BMC Med Imaging; 2013 Sep; 13():31. PubMed ID: 24028408
[TBL] [Abstract][Full Text] [Related]
30. The "Fingerprint" of Cancer Extends Beyond Solid Tumor Boundaries: Assessment With a Novel Ultrasound Imaging Approach.
Rao SR; Shelton SE; Dayton PA
IEEE Trans Biomed Eng; 2016 May; 63(5):1082-6. PubMed ID: 26394410
[TBL] [Abstract][Full Text] [Related]
31. In vivo targeted contrast enhanced micro-ultrasound to measure intratumor perfusion and vascular endothelial growth factor receptor 2 expression in a mouse orthotopic bladder cancer model.
Chan ES; Patel AR; Larchian WA; Heston WD
J Urol; 2011 Jun; 185(6):2359-65. PubMed ID: 21511281
[TBL] [Abstract][Full Text] [Related]
32. The use of three-dimensional ultrasound micro-imaging to monitor prostate tumor development in a transgenic prostate cancer mouse model.
Wu G; Wang L; Yu L; Wang H; Xuan JW
Tohoku J Exp Med; 2005 Nov; 207(3):181-9. PubMed ID: 16210828
[TBL] [Abstract][Full Text] [Related]
33. Angiogenesis imaging in the management of prostate cancer.
Padhani AR; Harvey CJ; Cosgrove DO
Nat Clin Pract Urol; 2005 Dec; 2(12):596-607. PubMed ID: 16474547
[TBL] [Abstract][Full Text] [Related]
34. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model.
Lee DJ; Lyshchik A; Huamani J; Hallahan DE; Fleischer AC
J Ultrasound Med; 2008 Jun; 27(6):855-66. PubMed ID: 18499845
[TBL] [Abstract][Full Text] [Related]
35. Ultrasound and magnetic resonance imaging for group stratification and treatment monitoring in the transgenic adenocarcinoma of the mouse prostate model.
Fagerland ST; Hill DK; van Wamel A; de Lange Davies C; Kim J
Prostate; 2020 Feb; 80(2):186-197. PubMed ID: 31763715
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
Pan J; Heiser A; Marget M; Steinmann J; Kabelitz D
Gene Ther; 2005 May; 12(9):742-50. PubMed ID: 15729371
[TBL] [Abstract][Full Text] [Related]
37. [Construction of a DNA vaccine against extracellular domain 1-3 of Flk1 and its inhibitory effect on growth of liver cancer cell line H22].
Lu F; Qin ZY; Li YM; Qi YX; Liu YF; Yang WB
Ai Zheng; 2004 Dec; 23(12):1616-21. PubMed ID: 15601548
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice.
Tseng JF; Farnebo FA; Kisker O; Becker CM; Kuo CJ; Folkman J; Mulligan RC
Surgery; 2002 Nov; 132(5):857-65. PubMed ID: 12464871
[TBL] [Abstract][Full Text] [Related]
39. Flk1-GFP BAC Tg mice: an animal model for the study of blood vessel development.
Ishitobi H; Matsumoto K; Azami T; Itoh F; Itoh S; Takahashi S; Ema M
Exp Anim; 2010; 59(5):615-22. PubMed ID: 21030789
[TBL] [Abstract][Full Text] [Related]
40. Molecular Ultrasound Imaging.
Baier J; Rix A; Kiessling F
Recent Results Cancer Res; 2020; 216():509-531. PubMed ID: 32594397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
